afm13 with cord blood-derived nk-cell therapy in patients with refractory cd30-positive lymphomas
Published 6 months ago • 262 plays • Length 2:55Download video MP4
Download video MP3
Similar videos
-
5:02
innate cell engager (ice®) afm13 combined with cord blood-derived nk cells for r/r cd30 lymphoma
-
2:41
a phase i/ii study of afm13 in combination with cord blood-derived nk cells in patients with r/r hl
-
1:35
redirect results: afm13 in patients with cd30 r/r ptcl
-
1:11
the future of cord blood-derived nk cells and how their persistence can be improved
-
2:54
ck0804, a cord blood-derived cellular therapy, in myelofibrosis with suboptimal ruxolitinib response
-
1:24
phase i study of cd123 nk cell engager sar443579 in r/r aml, b-all or hr-mds
-
2:41
an overview of the latest advances in hematology
-
1:04
clad-ldac-ven induction therapy in aml: insights from a phase ii trial
-
1:25
harnessing nk-cells to treat aml
-
2:02
alnuctamab, a bcma x cd3 tce, in the treatment of multiple myeloma
-
0:43
elm-2: qol and orr outcomes of odronextamab treatment for r/r fl
-
1:19
new treatments for aml
-
0:38
the functional role of cd4- and cd8-expressing t-cells in aml
-
0:36
the recent expanded fda approval of cilta-cel and ide-cel into earlier lines of myeloma treatment
-
1:33
cellular and non-cellular immunotherapies in cll
-
1:04
horizon scan of novel and upcoming aml therapies
-
3:40
social media for the hematologist
-
1:10
dr. joseph levine | hematology & oncology
-
3:45
imgn632: a novel cd123 adc for r/r aml and bpdcn